ImmunityBio, Inc. IBRX Gross Profit

Gross Profit at other companies

Bristol-Myers SquibbBMY

$9.25B+3.9%

Johnson & JohnsonJNJ

$17.26B+7.1%

Merck & Co.MRK

$12.09B-0.2%

Gilead SciencesGILD

$6.22B+11.5%

Nektar TherapeuticsNKTR

$21.81M+2.9%

Iovance Biotherapeutics, Inc.IOVA

$55.72M+403%

FAQ

What is ImmunityBio, Inc.'s gross profit?

ImmunityBio, Inc. (IBRX) reported gross profit of $43.97M in Q1 2026.

How has ImmunityBio, Inc.'s gross profit changed year-over-year?

ImmunityBio, Inc.'s gross profit increased by 167.1% year-over-year, from $16.46M to $43.97M.

What is the long-term trend for ImmunityBio, Inc.'s gross profit?

Over 3 years (2022 to 2025), ImmunityBio, Inc.'s gross profit has grown at a 676.9% compound annual growth rate (CAGR), from $240K to $112.54M.

What does gross profit mean?

Revenue minus cost of revenue — the profit available to cover operating expenses, representing the company's pricing power and production efficiency.